Key result
Left ventricular hypertrophy at the time of percutaneous coronary intervention was not independently associated with increased all-cause mortality at three years (HR 0.93; 95% CI 0.68-1.28; p=0.67).
Why the study?
Does the presence of left ventricular hypertrophy affect long-term survival in patients with coronary artery disease following percutaneous coronary intervention?
Cohort (n=4,284)
Yes
Does the presence of left ventricular hypertrophy affect long-term survival in patients with coronary artery disease following percutaneous coronary intervention?
Hazard Ratio: 0.93 (95% CI 0.68–1.28)
Absolute Event Rate: 14% vs 9%
p-value: p=0.67
Although patients with LVH undergoing PCI have higher unadjusted mortality, LVH is not an independent predictor of 3-year mortality after adjusting for baseline comorbidities.
Authors
No takes yet. Share an insight, caveat, or question.
LVH should not yet inform independent post-PCI mortality risk; leaves open its value in unadjusted or subgroup assessments.
David Brown (2009) conducted a cohort in Coronary artery disease (n=4,284). Left ventricular hypertrophy vs. No left ventricular hypertrophy was evaluated on All-cause mortality (HR 0.93, 95% CI 0.68-1.28, p=0.67). Left ventricular hypertrophy at the time of percutaneous coronary intervention was not independently associated with increased all-cause mortality at three years (HR 0.93; 95% CI 0.68-1.28; p=0.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: